Skip to main content

Table 1 Susceptibility of P. aeruginosa (245 isolates) Pathogens to Antimicrobials in the Latin America regiona from the 2018 PACTSb Database

From: Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis

 

% Susceptible

 

MIC (mg/mL)

Range

CLSIc

EUCASTc

Antimicrobial agent

50%

90%

 

%S

%I

%R

%S

%I

%R

Ceftolozane-tazobactam

0.5

4

0.12 to > 32

90.2

0.8

9.0

90.2

 

9.8

Amikacin

4

> 32

0.5 to > 32

83.6

1.2

15.2

79.1

4.5

16.4

Ampicillin-sulbactam

> 64

> 64

8 to > 64

      

Aztreonam

8

> 16

0.25 to > 16

64.1

13.5

22.4

77.6

 

22.4

Cefepime

2

32

0.25 to > 256

80.0

7.8

12.2

80.0

 

20.0

Ceftazidime

2

> 32

0.5 to > 32

77.1

6.1

16.7

77.1

 

22.9

Ceftriaxone

> 8

> 8

1 to > 8

      

Ciprofloxacin

0.12

> 16

≤0.03 to > 16

68.9

4.5

26.6

68.9

 

31.1

Colistin

0.5

1

≤0.06 to 2

100.0

 

0.0

100.0

 

0.0

Doripenem

0.5

8

≤0.06 to > 8

78.4

7.3

14.3

72.2

6.1

21.6

Gentamicin

2

> 16

≤0.12 to > 16

77.0

2.0

20.9

77.0

 

23.0

Imipenem

1

> 8

≤0.12 to > 8

74.3

3.7

22.0

78.0

 

22.0

Levofloxacin

0.5

32

0.03 to > 32

64.3

5.7

29.9

64.3

 

35.7

Meropenem

0.5

16

≤0.015 to > 32

73.5

7.8

18.8

73.5

12.2

14.3

Piperacillin-tazobactam

4

128

0.25 to > 128

74.3

12.2

13.5

74.3

 

25.7

Tigecycline

8

> 8

1 to > 8

      
  1. a Includes only Latin American countries (i.e., Argentina, Brazil, Chile, Costa Rica, Mexico, and Panama) with available data in the PACTS database
  2. bPACTS Program to Assess Ceftolozane/Tazobactam Susceptibility
  3. c Criteria as published by CLSI [2019] and EUCAST [2019]
  4. CLSI Clinical and Laboratory Standards Institute; EUCAST European Committee on Antimicrobial Susceptibility Testing; MIC minimum inhibitory concentration; PACTS Program to Assess Ceftolozane/Tazobactam Susceptibility